

CITATION REPORT

List of articles citing

Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score

DOI: 10.1016/j.urology.2006.02.042
Urology, 2006, 68, 318-23.

Source: <https://exaly.com/paper-pdf/39947075/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
533	Lower urinary tract symptoms (LUTS) in people aged 50 or older consulting general practitioners. 2007 , 7, 147-153		11
532	Evaluation of autonomic malfunction in idiopathic normal pressure hydrocephalus. 2008 , 18, 213-20		7
531	Urgency assessment in the evaluation of overactive bladder (OAB). 2008 , 27, 13-21		50
530	Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. 2008 , 15, 816-20		56
529	Causes of frequency and nocturia after renal transplantation. 2008 , 101, 1029-34		11
528	Re: Validation of the overactive bladder symptom score J. G. Blaivas, G. Panagopoulos, J. P. Weiss And C. Somaroo J Urol 2007; 178: 543-547. 2008 , 179, 791; author reply 791		0
527	Obstructive sleep apnea syndrome is associated with overactive bladder and urgency incontinence in men. 2009 , 32, 271-5		47
526	Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder. 2009 , 30, 287-94		36
525	Should an antimuscarinic agent be used for persistent LUTS after treatment with an alpha(1)-blocker?. 2009 , 6, 66-7		
524	Evaluation of urgency in women, with a validated Urgency, Severity and Impact Questionnaire (USIQ). 2009 , 20, 301-7		18
523	Measuring urgency in clinical practice. 2009 , 27, 739-45		9
522	Near infrared spectroscopy study of the central nervous activity during artificial changes in bladder sensation in men. 2009 , 16, 760-4		15
521	Clinical guideline for male lower urinary tract symptoms. 2009 , 16, 775-90		35
520	Symptom severity and patient perceptions in overactive bladder: how are they related?. 2009 , 104, 968-72		40
519	Differences and associations between nocturnal voiding/nocturia and sleep disorders. 2010 , 106, 232-7		24
518	Improvements in overactive bladder syndrome after polypropylene mesh surgery for cystocele. 2009 , 49, 226-31		9
517	Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. 2009 , 7, 13		21

516	Overactive Bladder in Female Patients with Chronic Diseases Visiting Primary Care Doctors: Effect of Age on Prevalence and Bothersomeness. 2009 , 1, 45-50		3
515	Strong Correlation Between the Overactive Bladder Symptom Score and Urgency Severity Score in Assessment of Patients With Overactive Bladder Syndrome. 2010 , 22, 82-86		7
514	Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. 2010 , 29, 482-7		47
513	Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. 2010 , 17, 796-800		16
512	Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. 2010 , 17, 931-6		17
511	The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. 2010 , 205251		7
510	Urine and Serum C-Reactive Protein Levels as Potential Biomarkers of Lower Urinary Tract Symptoms. 2010 , 21, 132-136		29
509	Validity of the Traditional Chinese Version of the King's Health Questionnaire for Taiwanese Patients With an Overactive Bladder. 2010 , 21, 180-184		2
508	Urgency is an independent factor for sleep disturbance in men with obstructive sleep apnea. <i>Urology</i> , 2010 , 76, 967-70	1.6	27
507	Urinary prostaglandin E ₂ was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome. <i>Urology</i> , 2010 , 76, 1267.e13-9	1.6	20
506	Conversion to Silodosin in Men on Conventional α -Blockers for Symptomatic Benign Prostatic Hyperplasia. 2010 , 2, 11-5		2
505	Are patients with the symptoms of overactive bladder and urodynamic detrusor overactivity different from those with overactive bladder but not detrusor overactivity?. 2011 , 74, 455-9		8
504	Botulinum Toxin in Urology. 2011 ,		4
503	Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. <i>Urology</i> , 2011 , 77, 60-4	1.6	68
502	Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. <i>Urology</i> , 2011 , 78, 126-33	1.6	87
501	Solifenacin may improve sleep quality in patients with overactive bladder and sleep disturbance. <i>Urology</i> , 2011 , 78, 648-52	1.6	9
500	Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes. <i>Urology</i> , 2011 , 78, 1040-5	1.6	72
499	Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia. <i>Urology</i> , 2011 , 78, 1058-62	1.6	12

498	Responsiveness and minimal clinically important change in overactive bladder symptom score. <i>Urology</i> , 2011 , 78, 768-73	1.6	49
497	Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study. 2011 , 3, 36-42		5
496	Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. 2011 , 3, 2-9		8
495	The Patient-Centric Approach: The Importance of Setting Realistic Treatment Goals. 2011 , 10, 23-27		3
494	Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial. 2011 , 18, 365-73		27
493	Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes. 2011 , 18, 483-7		11
492	Core lower urinary tract symptom score (CLSS) for the assessment of female lower urinary tract symptoms: a comparative study. 2011 , 18, 778-84		13
491	Outline of JUA clinical guidelines for benign prostatic hyperplasia. 2011 , 18, 741-56		52
490	JUA clinical guidelines for benign prostatic hyperplasia. 2011 , 18, e1-e33		4
489	Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. 2011 , 30, 1300-4		33
488	Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug. 2011 , 30, 1309-14		8
487	Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. 2011 , 30, 1448-55		67
486	Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study). 2011 , 2011, 854697		29
485	Immediate effect on overactive bladder symptoms following administration of imidafenacin. 2011 , 86, 330-3		6
484	The efficacy and safety of propiverine hydrochloride in patients with overactive bladder symptoms who poorly responded to previous anticholinergic agents. 2011 , 2011, 714978		9
483	Relation between expression of α 1-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. 2011 , 45, 15-9		22
482	Defining Causes for Overactive Bladder Symptoms in Women. 2012 , 4, 73-6		4
481	High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms. <i>Urology</i> , 2012 , 79, 260-5	1.6	21

480	Association between metabolic syndrome and male overactive bladder in a Japanese population based on three different sets of criteria for metabolic syndrome and the Overactive Bladder Symptom Score. <i>Urology</i> , 2012 , 79, 1372-8	1.6	22
479	Risk factors for new-onset overactive bladder in older subjects: results of the Fujiwara-kyo study. <i>Urology</i> , 2012 , 80, 71-6	1.6	32
478	Improvement of urinary dysfunction after kidney transplantation by administration of the antimuscarinic agent--prospective randomized controlled study. 2012 , 93, 597-602		4
477	A predictive factor in overactive bladder symptoms improvement after combined anterior vaginal wall prolapse repair: a pilot study. 2012 , 53, 405-9		4
476	Analysis of the risk factors for overactive bladder on the basis of a survey in the community. 2012 , 53, 541-6		16
475	B-type natriuretic peptide as an independent correlate of nocturnal voiding in Japanese women. 2012 , 31, 1266-71		11
474	The role of serum C-reactive protein in women with lower urinary tract symptoms. 2012 , 23, 935-40		31
473	Potential factors that can be used to differentiate between interstitial cystitis/painful bladder syndrome and bladder oversensitivity in women. 2012 , 66, 146-51		15
472	The presence of overactive bladder wet increased the risk and severity of erectile dysfunction in men with type 2 diabetes. 2012 , 9, 1913-22		15
471	Outcome Measurement of Overactive Bladder. 2012 , 4 Suppl 1, 62-6		
470	Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome. 2012 , 4 Suppl 1, 32-41		10
469	Prevalence and factors associated with overactive bladder and urinary incontinence in community-dwelling Taiwanese. 2012 , 24, 56-60		5
468	High frequency of overlap between functional dyspepsia and overactive bladder. 2012 , 24, 821-7		28
467	Higher glycosylated hemoglobin levels increase the risk of overactive bladder syndrome in patients with type 2 diabetes mellitus. 2012 , 19, 995-1001		44
466	Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score. 2012 , 109, 1512-6		24
465	Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ). 2012 , 23, 193-6		9
464	Widespread cortical and subcortical brain atrophy in Parkinson's disease with excessive daytime sleepiness. 2012 , 259, 318-26		31
463	Relationship between expression of B-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. 2013 , 32, 88-91		13

462	Ramelteon combined with an β -blocker decreases nocturia in men with benign prostatic hyperplasia. 2013 , 13, 30		2
461	Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria. 2013 , 111, 647-52		43
460	Correlation between overactive bladder symptoms and quality of life in Japanese male patients: focus on nocturia. <i>Urology</i> , 2013 , 82, 189-93	1.6	10
459	Correlation Between Bladder Mucosal Alpha-1D/Alpha-1A Adrenoceptor mRNA Ratio and Lower Urinary Tract Function in Benign Prostatic Obstruction Patients. 2013 , 5, 60-4		
458	Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. 2013 , 33, 71-91		26
457	International Prostate Symptom Score for assessing lower urinary tract dysfunction in women. 2013 , 24, 263-7		41
456	β -Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. 2013 , 45, 53-60		40
455	Development and validation of the Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome in a RESORT study. 2013 , 112, 276-82		19
454	Urge perception index of bladder hypersensitivity. 2013 , 189, 1797-803		4
453	Evaluation of factors influencing the natural history of nocturia in elderly subjects: results of the Fujiwara-kyo Study. 2013 , 189, 980-6		13
452	Modified prepubic TVT-obturator tape procedure versus the conventional method: a preliminary study. 2013 , 171, 376-80		1
451	Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite β -blocker treatment in patients with BPH: the ADDITION study. <i>Urology</i> , 2013 , 82, 887-93	1.6	31
450	Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study. 2013 , 90, 161-7		19
449	What are the factors contributing to failure in improvement of subjective symptoms following silodosin administration in patients with benign prostatic hyperplasia? Investigation using a pressure-flow study. 2013 , 32, 266-70		11
448	Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study. 2013 , 3,		26
447	Patient reported outcomes of abobotulinumtoxinA injection treatment for idiopathic detrusor overactivity: a pragmatic approach to management in secondary care. 2013 , 6, 59-63		4
446	Dietary Nutrients and Urinary Incontinence in Japanese Adults. 2013 , 5, 28-38		
445	The association between the self-perception period of overactive bladder symptoms and overactive bladder symptom scores in a non-treated population and related sociodemographic and lifestyle factors. 2013 , 67, 795-800		7

444	Who Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign Prostatic Hyperplasia?. 2013 , 5, 145-9	2
443	Twelve Months Follow-up of Injection of OnabotulinumtoxinA into Vesical Submucosa for Refractory Non-neurogenic Overactive Bladder. 2013 , 5, 55-9	
442	Burden of overactive bladder symptom on quality of life in stroke patients. 2013 , 32, 428-34	12
441	Randomized, Single-Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propriverine in the Treatment of Overactive Bladder. 2013 , 5, 11-6	2
440	Health-related quality of life in people with overactive bladder symptoms: reliability and validity of the traditional Chinese version of the Kings' Health Questionnaire. 2013 , 7, n/a-n/a	
439	Cortical and subcortical brain atrophy in Parkinson's disease with visual hallucination. 2013 , 28, 1732-6	53
438	New therapies in the treatment of overactive bladder. 2013 , 18, 319-37	8
437	Abstracts of the 43rd Annual Meeting of the International Continence Society (ICS), 26-30 August 2013, Barcelona, Spain. 2013 , 32, 507-932	4
436	Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms. 2014 , 9, 1021-30	5
435	A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency. 2014 , 9, e112063	
434	Transcutaneous electrical nerve stimulation in the treatment of patients with poststroke urinary incontinence. 2014 , 9, 851-6	26
433	Incidence and Dose-volume Analysis of Acute Bladder Toxicity following Pelvic Radiotherapy. 2014 , 100, 195-200	2
432	Patient-reported outcomes in overactive bladder due to idiopathic detrusor overactivity: A correlation of two multi-domain questionnaires with a focus on quality of life and lifestyle goals. 2014 , 7, 403-408	0
431	Hyposensitivity of C-fiber afferents at the distal extremities as an indicator of early stages diabetic bladder dysfunction in type 2 diabetic women. 2014 , 9, e86463	8
430	The prevalence and risk factors of OAB in middle-aged and old people in China. 2014 , 33, 387-91	26
429	Multicenter, randomized, sham-controlled study on the efficacy of magnetic stimulation for women with urgency urinary incontinence. 2014 , 21, 395-400	22
428	Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α -adrenoreceptor antagonist silodosin. 2014 , 21, 108-12	2
427	Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q). 2014 , 21, 505-11	6

426	Effect of propiverine hydrochloride on stress urinary incontinence. 2014 , 21, 1022-5	9
425	Finger taps and constipation are closely related to symptoms of overactive bladder in male patients with Parkinson's disease. 2014 , 21, 69-73	6
424	Clinical implications of a feeling of incomplete emptying with little post-void residue in men with lower urinary tract symptoms. 2014 , 33, 1123-7	7
423	Correlation of the Overactive Bladder Symptom Score, and the Voiding Diary and Urodynamic Parameters in Patients with Overactive Bladder Syndrome. 2014 , 6, 180-4	9
422	Nocturia Quality-of-Life questionnaire is a useful tool to predict nocturia and a risk of falling in Japanese outpatients: a cross-sectional survey. 2014 , 21, 289-93	7
421	Predictors of short-term overactive bladder symptom improvement after transurethral resection of prostate in men with benign prostatic obstruction. 2014 , 21, 1035-40	18
420	Tolterodine activates the prefrontal cortex during bladder filling in OAB patients: a real-time NIRS-urodynamics study. 2014 , 33, 1110-5	16
419	Linguistic validation of the English version of the Overactive Bladder Symptom Score. 2014 , 21, 229	9
418	Pathophysiology of gait dysfunction in normal pressure hydrocephalus. 63-69	1
417	Incontinence and lower urinary tract symptoms in normal pressure hydrocephalus. 80-90	1
416	OAB symptoms: assessment and discriminator for etiopathology. 2014 , 24, 345-51	5
415	Prediction of persistent storage symptoms after transurethral resection of the prostate in patients with benign prostatic enlargement. 2014 , 93, 425-30	17
414	Impact of transobturator tape treatment on overactive bladder symptoms, particularly nocturia, in patients with mixed urinary incontinence. 2014 , 55, 520-6	2
413	Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin. 2014 , 55, 608-14	13
412	Core lower urinary tract symptom score questionnaire: a psychometric analysis. 2014 , 21, 1151-4	2
411	Editorial Comment to Core lower urinary tract symptom score questionnaire: a psychometric analysis. 2014 , 21, 1154-5	
410	Does structured withdrawal of desmopressin improve relapse rates in patients with monosymptomatic enuresis?. 2014 , 192, 530-4	19
409	Psychometric validation of the English version of the overactive bladder symptom score. <i>Urology</i> , 2014 , 84, 46-50	1.6 13

408	Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms. 2014 , 23, 285-92		10
407	Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. 2014 , 46, 341-7		38
406	Overactive bladder in cervical spondylotic myelopathy. 2014 , 19, 22-5		2
405	Voiding characteristics and related hormonal changes in peri-menopausal and post-menopausal women: a preliminary study. 2014 , 79, 311-5		15
404	Is type-2 diabetes mellitus associated with overactive bladder symptoms in men with lower urinary tract symptoms?. <i>Urology</i> , 2014 , 84, 670-4	1.6	16
403	Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study. 2014 , 21, 389-94		15
402	Autonomic dysfunction and arterial stiffness in female overactive bladder patients and antimuscarinics related effects. 2014 , 79, 65-9		15
401	Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects. 2014 , 79, 428-34		11
400	Prevalence and associated risk factors of nocturia and subsequent mortality in 1,301 patients with type 2 diabetes. 2014 , 46, 1269-75		26
399	The impact of abdominal aortic calcification and visceral fat obesity on lower urinary tract symptoms in patients with benign prostatic hyperplasia. 2014 , 46, 1877-81		8
398	Self-created transobturator tape treatment of stress urinary incontinence without prior urodynamic investigation. 2014 , 182, 76-80		3
397	The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment. 2014 , 113, 506-12		14
396	Urinary nerve growth factor correlates with the severity of urgency and pain. 2014 , 25, 1561-7		22
395	First morning voided volume as a valuable tool for evaluating patients with overactive bladder. 2014 , 25, 79-82		2
394	[Neurological common diseases in the super-elder society. Topics: I. Usefulness of the newly-developed screening test for comprehensive geriatric assessment named "Dr. SUPERMAN"]. 2014 , 103, 1765-71		
393	Pumpkin Seed Oil Extracted From Cucurbita maxima Improves Urinary Disorder in Human Overactive Bladder. 2014 , 4, 72-4		46
392	Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. 2015 , 22, 835-41		28
391	Prevalence of overactive bladder and its related factors in Japanese patients with diabetes mellitus. 2015 , 62, 847-54		17

390	Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). 2015 , 116, 612-22	65
389	Characterization of symptom bother and health-related quality of life in Japanese female patients with overactive bladder. 2015 , 34, 730-5	9
388	Symptom score change and patient versus doctor satisfaction in overactive bladder before and after anti-muscarinic treatment. 2015 , 41, 957-61	1
387	The multidimensional sensation of desire to void differs between people with and without overactive bladder. 2015 , 34, 444-9	3
386	Association between Chronic Periodontal Disease and Lower Urinary Tract Symptoms in Both Sexes. 2015 , 7, 17-21	2
385	NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome. 2015 , 56, 204-11	14
384	Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder. 2015 , 41, 1132-40	8
383	A survey on the management of overactive bladder by Indonesian urologists. 2015 , 24, 91-6	1
382	Clinical Outcomes and Urodynamic Effects of Tailored Transvaginal Mesh Surgery for Pelvic Organ Prolapse. 2015 , 2015, 191258	7
381	Comparison of solifenacin and fesoterodine in treatment of overactive bladder. 2015 , 36, 1181-5	5
380	Comprehensive Health-Related Quality of Life is Influenced by Nocturia and Sleep Disturbance: Investigation Based on the SF-8. 2016 , 62, 9-16	8
379	Improvement of overactive bladder symptoms after tension-free vaginal mesh operation in women with pelvic organ prolapse: Correlation with preoperative urodynamic findings. 2015 , 22, 577-80	11
378	Stemming the Tide: Infectious Complications After Prostate Biopsy. 2015 , 33, 893, 896-7	1
377	Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study. 2015 , 56, 305-9	1
376	A prospective, observational study to assess the association between dry mouth and solifenacin treatment in patients with overactive bladder syndrome. 2015 , 47, 235-42	2
375	Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder. 2015 , 26, 7-16	3
374	EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. 2015 , 67, 1099-1109	541
373	Effect of the continuous positive airway pressure on the nocturnal urine volume or night-time frequency in patients with obstructive sleep apnea syndrome. <i>Urology</i> , 2015 , 85, 333-6	1.6 29

372	Descriptors of sensation confirm the multidimensional nature of desire to void. 2015 , 34, 161-6		6
371	Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. <i>Urology</i> , 2015 , 85, 786-90	1.6	28
370	[Diagnosis of overactive bladder (OAB)]. 2015 , 54, 421-7; quiz 428-9		1
369	Effects of electroacupuncture on overactive bladder refractory to anticholinergics: a single-blind randomised controlled trial. 2015 , 33, 368-74		12
368	Non-inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: a multicenter, randomized, parallel-group study. 2015 , 22, 311-6		5
367	A Slow Stream Is Pathophysiologically Related to a Poor Response to α -Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia. <i>Urology</i> , 2015 , 86, 558-64	1.6	4
366	Improvement of nocturia and sleep disturbance by silodosin in male patients with lower urinary tract symptoms. 2015 , 22, 236-8		3
365	A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. 2015 , 193, 921-6		71
364	Predictive risk factors of postoperative urinary incontinence following holmium laser enucleation of the prostate during the initial learning period. 2016 , 42, 740-6		21
363	Obstructive sleep apnea syndrome should be considered as a cause of nocturia in younger patients without other voiding symptoms. 2016 , 10, E241-E245		7
362	Review of Cucurbita pepo (Pumpkin) its Phytochemistry and Pharmacology. 2016 , 6,		46
361	Association between ambient temperature and lower urinary tract symptoms: a community-based survey. 2016 , 42, 521-30		7
360	Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM-net). 2016 , 11, 69		22
359	Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study. 2016 , 70, 351-7		8
358	Comparison of the overactive bladder symptom score and the overactive bladder symptom score derived from the bladder diaries. 2016 , 35, 349-53		3
357	Patient Satisfaction After Sling Revision for Voiding Dysfunction After Sling Placement. 2016 , 22, 140-5		8
356	Clinical assessment and prevalence of parkinsonism in Japanese elderly people. 2016 , 133, 373-9		13
355	The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial. 2016 , 16, 49		6

354	Measuring Clinical Outcomes in Overactive Bladder Interventions: We Can Do Better. 2016 , 70, 806-807	
353	Association between obesity and lower urinary tract symptoms: propensity score matching study between healthy controls and obese patients seeking bariatric surgery. 2016 , 12, 1585-1593	13
352	Intravesical botulinum toxin-A: Does the injection template matter?. 2016 , 9, 256-261	1
351	Sleep Apnea and Circadian Extracellular Fluid Change as Independent Factors for Nocturnal Polyuria. 2016 , 196, 1183-9	5
350	Systemic Nonurological Symptoms in Patients with Overactive Bladder. 2016 , 196, 467-72	12
349	Urinary dysfunction and motor symptoms in untreated Parkinson's disease. 2016 , 365, 147-50	6
348	A Narrative Review of Patient-reported Outcomes in Overactive Bladder: What is the Way of the Future?. 2016 , 70, 799-805	17
347	Practical Index of Urinary Incontinence Following Holmium Laser Enucleation of the Prostate: A Case-Series Study of the 24-Hour Pad Test Immediately after Catheter Removal. 2016 , 97, 310-319	5
346	Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study). 2016 , 23, 1016-1023	6
345	Clinical Guideline for Female Lower Urinary Tract Symptoms. 2016 , 8, 5-29	29
344	Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochloride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. 2016 , 8, 38-43	9
343	The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α -adrenergic receptor blocker monotherapy: prospective analysis of elderly men. 2016 , 16, 45	18
342	Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder. 2016 , 23, 866-872	4
341	Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. 2016 , 97, 325-329	10
340	Prevalence of overlap syndromes and symptoms in pediatric functional dyspepsia. 2016 , 16, 75	19
339	Impact of ao-dake-humi, Japanese traditional bamboo foot stimulator, on lower urinary tract symptoms, constipation and hypersensitivity to cold: a single-arm prospective pilot study. 2016 , 16, 513	1
338	Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open-label, controlled comparison study. 2016 , 23, 451-7	6
337	Nocturia indicates a poor health status and increases mortality in male patients with type 2 diabetes mellitus. 2016 , 48, 1209-1214	12

336	Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome. 2016 , 25, 2021-9		13
335	Survey and Risk Factors for Lower Urinary Tract Storage Symptoms in Middle-Aged and Older Stroke Patients in Urban China. 2016 , 8, 91-9		5
334	OAB epidemiological survey of general gynaecology outpatients and its effects on patient quality of life. 2016 , 35, 29-35		5
333	Influence of urinary urgency and other urinary disturbances on falls in Parkinson's disease. 2016 , 360, 153-7		24
332	Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder. 2017 , 9, 27-32		9
331	Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study). 2017 , 36, 1097-1103		7
330	Assessment of voiding dysfunction in Parkinson's disease: Reliability and validity of the Turkish version of the Danish Prostate Symptom Score. 2017 , 36, 1903-1909		3
329	A questionnaire survey to assess lower urinary tract symptoms in patients with chronic stroke. 2017 , 36, 1890-1895		6
328	Association of urinary nerve growth factor levels with erectile function in young men with type 2 diabetes mellitus. 2017 , 29, 101-104		4
327	Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia. <i>Urology</i> , 2017 , 106, 153-159	1.6	3
326	Effects of Withdrawing α -Blocker from Combination Therapy with α -Blocker and 5 α -Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics. 2017 , 198, 905-912		6
325	Prevalence of overactive bladder and its impact on quality of life in 1025 patients with type 2 diabetes in mainland China. 2017 , 31, 1254-1258		7
324	Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DirecT Study). 2017 , 24, 525-531		14
323	Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score. 2017 , 16, 806-814		2
322	Overactive Bladder Symptom Scores responsiveness before and after anticholinergic treatment in women with overactive bladder: The pilot study. 2017 , 43, 1189-1193		
321	Improvement of voiding characteristics in morbidly obese women after bariatric surgery: A single-center study with a 1-year follow-up. 2017 , 13, 836-841		11
320	Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder. 2017 , 7, 437-53		10
319	Clinical and urodynamic assessment in patients with pelvic organ prolapse before and after laparoscopic sacrocolpopexy. 2017 , 28, 1543-1549		23

318	Critical evaluation of the overactive bladder and urgency urinary incontinence association with obstructive sleep apnea syndrome in a relatively young adult male population. 2017 , 36, 1804-1808		9
317	Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial. <i>Urology</i> , 2017 , 100, 59-64	1.6	22
316	Measurement of Nonmotor Symptoms in Clinical Practice. 2017 , 133, 291-345		9
315	A case series of pelvic fracture patients who developed lower urinary tract symptoms after transarterial embolization of bilateral internal iliac arteries. 2017 , 4, 358-362		1
314	Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder. 2017 , 24, 100-104		5
313	Toileting behaviors and overactive bladder in patients with type 2 diabetes: a cross-sectional study in China. 2017 , 17, 42		5
312	A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015. 2017 , 35, 33-50		156
311	Effects of laser procedure for female urodynamic stress incontinence on pad weight, urodynamics, and sexual function. 2017 , 28, 469-476		53
310	A community-based epidemiological survey of overactive bladder and voiding dysfunction in female Taiwanese residents aged 40 years and above. 2017 , 56, 811-814		2
309	Prostatic vascular damage induced by cigarette smoking as a risk factor for recovery after holmium laser enucleation of the prostate (HoLEP). 2017 , 8, 14039-14049		2
308	Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines. 2017 , 11, 61-64		36
307	Effectiveness of physical activity as primary preventive care for lower urinary tract symptoms in elderly people through the ". 2017 , 29, 1167-1170		2
306	Female Functional Constipation Is Associated with Overactive Bladder Symptoms and Urinary Incontinence. 2017 , 2017, 2138073		16
305	Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute. 2017 , 17, 62		11
304	Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study. 2017 , 17, 108		21
303	Treatment Results of Transurethral Resection of the Prostate by Non-Japanese Board-Certified Urologists for Benign Prostate Hyperplasia: Analysis by Resection Volume. 2017 , 84, 73-78		1
302	Correlation between overactive bladder symptom score and neuropsychological parameters in Alzheimer's disease patients with lower urinary tract symptom. 2017 , 43, 256-263		8
301	Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality. 2017 , 32, 1491-1495		4

300	A ureteral stent crossing the bladder midline leads to worse urinary symptoms. 2017 , 70, 412-417	4
299	Prospective randomized study evaluating ultrasound versus fluoroscopy guided sacral InterStim [®] lead placement: A pilot study. 2018 , 37, 1737-1743	7
298	Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients. 2018 , 41, 98-102	14
297	Risk factors of overactive bladder syndrome and its relation to sexual function in menopausal women. 2018 , 85, 10-14	11
296	De novo overactive bladder after robot-assisted laparoscopic radical prostatectomy. 2018 , 37, 2008-2014	15
295	Medical treatment of female overactive bladder syndrome and treatment-related effects. 2018 , 117, 871-878	7
294	Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia. 2018 , 200, 620-625	4
293	Relation of overactive bladder with motor symptoms and dopamine transporter imaging in drug-naïve Parkinson's disease. 2018 , 50, 37-41	8
292	Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?. 2018 , 222, 75-79	7
291	Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy. 2018 , 378, 529-538	49
290	Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary. 2018 , 37, 1701-1710	3
289	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. 2018 , 5, 479-491	12
288	Laparoscopic Organopexy with Non-mesh Genital (LONG) Suspension: A Novel Uterine Preservation Procedure for the Treatment of Apical Prolapse. 2018 , 8, 4872	3
287	Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year. 2018 , 10, 21-26	2
286	Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial. 2018 , 10, 148-152	22
285	Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective B-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?. 2018 , 10, 158-166	5
284	Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study. 2018 , 10, 215-220	4
283	The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review. 2018 , 37, 528-541	35

282	Cross-Sectional Epidemiological Analysis of the Nagahama Study for Correlates of Overactive Bladder: Genetic and Environmental Considerations. 2018 , 199, 774-778	10
281	A kit ligand, stem cell factor as a possible mediator inducing overactive bladder. 2018 , 37, 1258-1265	3
280	Prevalence and Risk Factors of Urinary Incontinence and Overactive Bladder in Japanese Women. 2018 , 10, 308-314	16
279	The Overactive Bladder Symptom Score, International Prostate Symptom Score-Storage Subscore, and Urgency Severity Score in Patients With Overactive Bladder and Hypersensitive Bladder: Which Scoring System is Best?. 2018 , 22, 99-106	17
278	Effectiveness and safety of moxibustion for alleviating symptoms of overactive bladder: A prospective, randomized controlled, crossover-design, pilot study. 2018 , 97, e12016	3
277	Muscarinic cholinergic signaling and overactive bladder-like symptoms associated with invasive bladder cancer. 2018 , 16, 775-784	2
276	Impact of the mid-urethral sling for stress urinary incontinence on female sexual function and their partners' sexual activity. 2018 , 57, 853-857	5
275	Effectiveness of neuromuscular electrical stimulation therapy in patients with urinary incontinence after stroke: A randomized sham controlled trial. 2018 , 97, e13702	11
274	ROK study-C (Rainbow of KIBOU study-colorectum): a colorectal cancer survivor cohort study on food, nutrition, physical activity, psychosocial factors and its influences on colorectal cancer recurrence, survival and quality of life in Japan. 2018 , 18, 953	3
273	Electroacupuncture to treat with Overactive Bladder in Postmenopausal Women: study protocol for a multicenter, randomized, controlled, parallel clinical trial. 2018 , 19, 493	
272	Risk factors and factors affecting the severity of overactive bladder symptoms in Korean women who use public health centers. 2018 , 61, 404-412	7
271	The association between local atherosclerosis of the prostatic artery and benign prostatic enlargement in humans: Putative mechanism of chronic ischemia for prostatic enlargement. 2018 , 78, 1001-1012	9
270	Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder. 2018 , 70, 1133-1138	1
269	Effects of an education program on toileting behaviors and bladder symptoms in overactive bladder patients with type 2 diabetes: A randomized clinical trial. 2018 , 87, 131-139	5
268	A Review of Scales to Evaluate Sleep Disturbances in Movement Disorders. 2018 , 9, 369	29
267	Diagnostic Work-up of LUTS/BPH: From Standard to New Perspectives. 2018 , 113-133	
266	Effectiveness and safety of acupuncture for elderly overactive bladder population in Hong Kong: study protocol for a randomized controlled trial. 2018 , 19, 376	6
265	Usefulness of the frequency-volume chart over the International Prostate Symptom Score in patients with benign prostatic hyperplasia in view of global polyuria. 2018 , 13, e0197818	1

264	Overactive bladder symptom severity, bother, help-seeking behavior, and quality of life in patients with type 2 diabetes: a path analysis. 2018 , 16, 1	44
263	Overactive bladder induces transient hypertension. 2018 , 11, 196	4
262	Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics. 2018 , 10, 263-272	3
261	Sleep Disturbance Has a Higher Impact on General and Mental Quality of Life Reduction than Nocturia: Results from the Community Health Survey in Japan. 2019 , 5, 1120-1126	11
260	Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients. 2019 , 118, 279-284	5
259	Reliability of the Polish version of the Overactive Bladder Symptom Score (OABSS) questionnaire : Correlation of the OABSS with urodynamic study and the UDI-6 and IIQ-7 questionnaires. 2019 , 30, 2135-2139	3
258	Delivery of intravesical botulinum toxin A using low-energy shockwaves in the treatment of overactive bladder: A preliminary clinical study. 2019 , 17, 216-220	5
257	Fesoterodine normalizes the brain function in overactive bladder patients due to central nervous system lesion: A real-time measure of oxyhemoglobin concentration changes during urodynamics. 2019 , 26, 1014-1015	1
256	Validation of the Arabic linguistic version of the Overactive Bladder Symptoms Score questionnaire. 2019 , 17, 265-269	7
255	Gait speed and overactive bladder in the healthy community-dwelling super elderly: The Sukagawa Study. 2019 , 38, 2324-2332	10
254	The impact of frailty on treatment for overactive bladder in older adults. 2019 , 38, 1915-1923	7
253	Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial. 2019 , 20, 446	2
252	Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response. 2019 , 30, 2121-2126	4
251	Risk factors associated with the progression of overactive bladder among patients with type 2 diabetes. 2019 , 73, e13395	2
250	Acupuncture for overactive bladder in adults: a systematic review and meta-analysis. 2019 , 37, 321-331	7
249	Epidemic investigation of benign prostatic obstruction with coexisting overactive bladder in Shanghai Pudong New Area and its impact on the health-related quality of life. 2019 , 19, 82	1
248	What Are Factors Contributing to Improvement of Overactive Bladder Symptoms after Alpha-1 Blocker Treatment in Patients with Both Storage and Voiding Symptoms?. 2019 , 103, 439-443	1
247	Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and B-adrenoceptor agonists. 2019 , 37, 2459-2466	14

246	Abnormal Brain Functional Connectivity Strength in the Overactive Bladder Syndrome: A Resting-State fMRI Study. <i>Urology</i> , 2019 , 131, 64-70	1.6	9
245	Association between Sarcopenia and Overactive Bladder in Elderly Diabetic Patients. 2019 , 23, 532-537		3
244	The probability of re-treatment after discontinuation of a 3-month versus a 6-month course of solifenacin for female overactive bladder: A prospective randomized controlled study. 2019 , 126, 11-17		1
243	Development and validation of Sasang Urination and Defecation Inventory (SUDI) for pathophysiological symptoms of Sasang typology. 2019 , 8, 82-88		3
242	Outcomes for Intravesical Abobotulinumtoxin A (Dysport) Treatment in the Active Management of Overactive Bladder Symptoms-A Prospective Study. <i>Urology</i> , 2019 , 130, 54-58	1.6	4
241	Unintentional body movement parameters and pulse rate variability parameters are associated with the desire to void. 2019 , 68, 116-121		
240	Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study. 2019 , 17, 143-149		3
239	Association of CCL2, CCR2 and CCL5 genetic polymorphisms with the development and progression of benign prostatic hyperplasia. 2019 , 41, 2491-2501		4
238	Überaktive Blase – Aktuelle diagnostische und therapeutische Aspekte. 2019 , 52, 188-194		
237	Validation of a novel digital health monitoring system to measure the volume of voided urine. 2019 , 38, 1106-1110		4
236	Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients. 2019 , 124, 242-250		23
235	Does successful treatment of overactive bladder improve co-morbidities in patients with nocturia?. 2019 , 38, 242-248		0
234	Relationship between Lower Urinary Tract Dysfunction and Clinical Features in Chinese Parkinson's Disease Patients. 2019 , 2019, 6820937		4
233	Effect of ureteral stent diameter on ureteral stent-related symptoms. 2019 , 11, 195-199		4
232	Gentle Perineal Skin Stimulation for Control of Nocturia. 2019 , 302, 1824-1836		
231	Effect of Er:YAG Laser for Women with Stress Urinary Incontinence. 2019 , 2019, 7915813		16
230	Evaluation of Lower Urinary Tract Symptoms (LUTS): Severity Score and Symptom Association. 2019 , 4, 684-687		
229	[LSC (LAPAROSCOPIC SACROCOLPOPEXY) VERSUS UPHOLD TYPE TVM: A CASE CONTROL STUDY]. 2019 , 110, 112-118		1

228	Role of Serum and Urinary Biomarkers in Evaluation and Management of Patients With Overactive Bladder. 2019 , 12, 117956111986490	1
227	Predictors for de novo stress urinary incontinence following pelvic reconstruction surgery with transvaginal single-incisional mesh. 2019 , 9, 19166	2
226	Relationship between oxidative stress and lower urinary tract symptoms: results from a community health survey in Japan. 2019 , 123, 877-884	16
225	Relationships among occupational stress, toileting behaviors, and overactive bladder in nurses: A multiple mediator model. 2019 , 75, 1263-1271	3
224	Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB. 2019 , 11, O180-O185	0
223	Atherosclerosis as a predictor of transient exacerbation of overactive bladder symptoms after robot-assisted laparoscopic radical prostatectomy. 2019 , 26, 234-240	1
222	Contemporary Pharmacotherapy of Overactive Bladder. 2019 ,	
221	Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study. 2019 , 11, 48-55	36
220	Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder. 2019 , 11, 56-60	0
219	Feeling of incomplete emptying with little post-void residual in patients with lower urinary tract symptoms: Clinical implications and treatment outcomes. 2019 , 11, O59-O64	4
218	Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with α blocker and dutasteride to combination therapy with tadalafil and dutasteride. 2020 , 23, 501-506	4
217	Prevalence and clinical characteristics of overactive bladder in systemic sclerosis. 2020 , 30, 327-331	3
216	A systematic approach to the investigation and treatment of nocturia. 2020 , 13, 99-105	
215	Short-term benefits of balneotherapy for patients with chronic pelvic pain: a pilot study in Korea. 2020 , 40, 520-525	3
214	Case-finding tools for the diagnosis of OAB in women: A narrative review. 2020 , 39, 13-24	1
213	Effect of mirabegron on erectile function in sexually active men with bothersome overactive bladder symptoms. 2020 , 83, 55-59	2
212	Evaluation of Choline and Acetylcholine Levels in Responders and Nonresponders to Anticholinergic Therapy for Overactive Bladder Syndrome. 2020 , 26, e91-e96	2
211	Predictive factors for persistence of preoperative overactive bladder symptoms after transvaginal mesh surgery in women with pelvic organ prolapse. 2020 , 12, 167-172	2

210	[Concepts and assessment methods in lower urinary tract symptoms: From symptom score to Patient-Reported Outcomes and Outcomes (PRO)]. 2020 , 30, 181-189	0
209	Exploring pelvic floor muscle activity in men with lower urinary tract symptoms. 2020 , 39, 732-737	5
208	The role of intravesical prostatic protrusion in the evaluation of overactive bladder in male patients with LUTS. 2020 , 52, 815-820	1
207	Urinary Function of the Sasang Type and Cold-Heat Subgroup Using the Sasang Urination Inventory in Korean Hospital Patients. 2020 , 2020, 7313581	0
206	Magnetic resonance image connectivity analysis provides evidence of central nervous system mode of action for parasacral transcutaneous electro neural stimulation - A pilot study. 2020 , 16, 536-542	1
205	Polysomnography and Nocturia Evaluations after Uvulopalatopharyngoplasty for Obstructive Sleep Apnea Syndrome. 2020 , 9,	0
204	Prevalence of detrusor underactivity and bladder outlet obstruction in women with cystocele and changes in voiding function after cystocele repair. 2020 , 119, 1764-1771	1
203	Overactive bladder medication: Persistence, drug switching, and reinitiation. 2020 , 39, 2527-2534	5
202	New combined surgery for cervical cancer complicated by pelvic organ prolapse using autologous fascia lata: A case report. 2020 , 8, 1382-1386	1
201	Effects of saw palmetto fruit extract intake on improving urination issues in Japanese men: A randomized, double-blind, parallel-group, placebo-controlled study. 2020 , 8, 4017-4026	2
200	500 Cases of High-intensity Focused Ultrasound (HIFU) Ablated Uterine Fibroids and Adenomyosis. 2020 , 59, 865-871	12
199	Quality of life and the prevalence of urinary incontinence after surgical treatment for gynecologic cancer: a questionnaire survey. 2020 , 20, 148	0
198	Lower Urinary Tract Symptoms (LUTS) and Sexual Function and Dysfunction. 2020 ,	0
197	Impact of Cold Indoor Temperatures on Overactive Bladder: A Nationwide Epidemiological Study in Japan. <i>Urology</i> , 2020 , 145, 60-65	1.6 1
196	Low-Intensity Extracorporeal Shock Wave Therapy Ameliorates the Overactive Bladder: A Prospective Pilot Study. 2020 , 2020, 9175676	5
195	Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO. 2021 , 39, 2049-2054	1
194	Sixty-minute uroflowmetry: A pilot study. 2020 , 27, 1050-1051	
193	Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder. 2020 , 27, 899-904	2

- 192 Impact of smoking habit on overactive bladder symptoms and incontinence in women. **2020**, 27, 1078-1086 8
- 191 The impact of smoking on male lower urinary tract symptoms (LUTS). **2020**, 10, 20212 2
- 190 Behavioural interventions for nocturia in adults. **2020**,
- 189 Treatment of Overactive Bladder in the Frail Patient. **2020**, 15, 386-392
- 188 Obstructive Sleep Apnea Syndrome as a Potential Cause of Nocturia in Younger Adults. *Urology*, **2020**, 143, 42-47 1.6 3
- 187 Voiding time as a predictor for urinary tract function and health status. **2020**, 20, 670-673
- 186 Predictors of an improvement in the severity of concomitant urodynamic stress incontinence after transvaginal mesh surgery for pelvic organ prolapse. **2020**, 119, 917-924 2
- 185 Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. **2020**, 15, 175 2
- 184 The impact of microalbuminuria on overactive bladders: Results from a community-based four-year longitudinal study in Japan. **2020**, 39, 1567-1575 1
- 183 Response to Letter. **2020**, 135, 483-484
- 182 Providing Patient-Centered Perinatal Care for Transgender Men and Gender-Diverse Individuals: A Collaborative Multidisciplinary Team Approach. **2020**, 135, 484
- 181 OnabotulinumtoxinA (botulinum toxin typeA) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phaseIII, randomized, double-blind, placebo-controlled trial (interim analysis). **2020**, 27, 227-234 7
- 180 Readability of pelvic floor dysfunction questionnaires. **2020**, 39, 813-818 6
- 179 Evaluation of Urine Choline Levels in Women With and Without Overactive Bladder Syndrome. **2020**, 26, 644-648 1
- 178 Overactive Bladder in Women: an Update for Primary Care Physicians. **2020**, 15, 44-52
- 177 Evaluation and Treatment of Overactive Bladder in Women. **2020**, 95, 370-377 13
- 176 Useful parameters to predict the presence of detrusor overactivity in male patients with lower urinary tract symptoms. **2020**, 39, 1394-1400 1
- 175 Response to Letter. **2020**, 135, 484-485

174	Therapeutic effects of Low intensity extracorporeal low energy shock wave therapy (LiESWT) on stress urinary incontinence. 2020 , 10, 5818		6
173	Laparoscopic Long Mesh Surgery with Augmented Round Ligaments: A Novel Uterine Preservation Procedure For Apical Pelvic Organ Prolapse. 2020 , 10, 6615		2
172	Complications and clinical outcomes of laparoscopic sacrocolpopexy for pelvic organ prolapse. 2021 , 41, 128-132		3
171	The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan. 2021 , 39, 169-175		3
170	Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?. 2021 , 32, 1117-1127		3
169	Altered gut microbiome associated with overactive bladder and daily urinary urgency. 2021 , 39, 847-853		6
168	Sex Differences in Prevalence and Patient Behavior Regarding Lower Urinary Tract Symptoms Among Japanese Medical Checkup Examinees. <i>Urology</i> , 2021 , 151, 24-30	1.6	0
167	Electroacupuncture for post-stroke overactive bladder: a multi-centre pilot randomized controlled trial. 2021 , 39, 175-183		2
166	Association of advanced glycation end-product accumulation with overactive bladder in community-dwelling elderly: A cross-sectional Sukagawa study. 2021 , 8, 189-196		
165	The Correlation between Severity of Overactive Bladder Symptoms with Female Sexual Dysfunction and Sexual Satisfaction of Partners. 2021 , 105, 124-130		2
164	The impact of overactive bladder on health-related quality of life in Korea: based on the results of a Korean Community Health Survey. 2021 , 30, 1017-1024		0
163	Prevalence of xerostomia with or without overactive bladder symptoms. 2021 , 13, 224-229		1
162	Does Depression Contribute to the Bladder and Bowel Complaint in Parkinson's Disease Patients?. 2021 , 8, 240-244		4
161	Efficacy of cinnamon patch treatment for alleviating symptoms of overactive bladder: A double-blind, randomized, placebo-controlled trial. 2021 , 80, 153380		3
160	Long-term chronological changes in urination status of patients who underwent ileal neobladder reconstruction at a single institution. 2021 , 53, 275-280		
159	Regional brain atrophy in overactive bladder syndrome: a voxel based morphometry study. 2021 , 53, 27-33		1
158	Urgency urinary incontinence, loss of independence, and increased mortality in older adults: A cohort study. 2021 , 16, e0245724		1
157	The Correlation amongst Salty Taste Preference and Overactive Bladder Symptoms in Female Individuals. 2021 , 18,		

156	Social innovation for life expectancy extension utilizing a platform-centered system used in the lwaki health promotion project: A protocol paper. 2021 , 9, 20503121211002606	6
155	The Effect of Transcutaneous Posterior Tibial Nerve Stimulation on the Overactive Bladder in a Child: A Case Study. 2021 , 8,	1
154	Validating 7-items Overactive Bladder Symptom Score (OABSS) through Arabic linguistic version. 2021 , 11, 661	1
153	Does cognitive behavioral therapy using a self-check sheet improve night-time frequency in patients with nocturia? Results of a multicenter randomized controlled trial. 2021 , 28, 444-449	1
152	The clinical research of 5 steps sequential method for whole treatment of hemorrhagic radiation cystitis in china. 2021 , 18, 756-762	1
151	A 3-year longitudinal survey of overactive bladder in community-dwelling male residents aged 40 years and above. 2021 , 13, 356-360	
150	Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake. 2021 , 11, 4046	2
149	Cohort profile: A super-elderly population-based cohort in Japan (the Sukagawa Study). 2021 , 50, 727-727h	2
148	Presurgical bladder wall thickness is a useful marker to predict the postsurgical improvement of symptoms in patients with pelvic organ prolapse-related overactive bladder. 2021 , 13, 347-355	1
147	Urodynamic evaluation of patients with localized prostate cancer before and 4 months after robotic radical prostatectomy. 2021 , 11, 3632	1
146	Predisposing factors of persistent storage symptoms after holmium laser enucleation of the prostate in patients with benign prostatic hyperplasia and their correlations to the symptom recovery period. 2021 , 101, 305	
145	Feasibility and Effectiveness of an Interprofessional Mindfulness-Informed Group-Based Intervention for Treatment of Overactive Bladder: A Pilot Study. 2021 , 45, 76-82	
144	Evaluation of the relationship of cholinergic metabolites in urine and urgency urinary incontinence. 2021 , 1	
143	Prevalence and associated risk factors among patients with overactive bladder syndrome in Pakistan. 2021 , 37, 1185-1189	
142	Triple-disease etiology is common for LUTS in octogenarians: a neuro-urological approach. 2021 , 53, 1507-1513	2
141	Walking-Evoked Erection in Patients with Lumbar Degenerative Diseases: Eight Cases and Review of the Literature. 2021 , 15, 172-179	0
140	Dietary glycine improves urine storage symptoms in urology outpatients. 2021 , 18, 617-620	1
139	Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series. 2021 , 4, 251-254	

- 138 Effects of overactive bladder syndrome on female sexual function. **2021**, 100, e25761 0
- 137 Protocol for development and validation of a prediction model for 5-year risk of incident overactive bladder in the general population: the Nagahama study. **2021**, 21, 78 0
- 136 Intermediate-term results of a prospective, multicenter study on remote programming sacral neuromodulation for refractory overactive bladder. **2021**, 10, 1966-1975 0
- 135 Clinical Observation of the Correlation Between Overactive Bladder and Atopic Constitution in Children. **2021**, 9, 646118 1
- 134 Postpartum voiding dysfunction following vaginal versus caesarean delivery. **2021**, 1-5
- 133 The 1-year continuation rate and discontinuation factors of vibegron and mirabegron: A retrospective comparative study in a rehabilitation hospital in Japan. **2021**, 13, 448-455 0
- 132 Beraktive Blase (OAB) beim Mann. **2021**, 23, 97-103
- 131 Association between female urinary urgency and aponeurotic ptosis: Results from a community-based cross-sectional study in Japan. **2021**, 40, 1678-1685
- 130 Diagnostic Potential of Low Serum Platelet, Albumin and Prolong PT-INR for Overactive Bladder and Nocturia in Chronic Hepatitis-Related Liver Cirrhosis. **2021**, 10, 0
- 129 Low Intensity Extracorporeal Shock Wave Therapy as a Potential Treatment for Overactive Bladder Syndrome. **2021**, 10, 1
- 128 Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial. **2021**, 53, 2243-2250 0
- 127 Association between overactive bladder and pelvic organ mobility as evaluated by dynamic magnetic resonance imaging. **2021**, 11, 13726 1
- 126 Overflow Urinary Incontinence with Herniated Lumbar Disc Managed by Korean Medicine Therapy: A Case Report. **2021**, 31, 125-131
- 125 Efficacy of Transcutaneous Electrical Nerve Stimulation in the Management of Neurogenic Overactive Bladder: A Randomized Controlled Trial. **2021**, 101, 0
- 124 Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: a nationwide registry study in Japan. **2021**, 16, 355 3
- 123 Low-Intensity Extracorporeal Shock Wave Therapy Promotes Bladder Regeneration and Improves Overactive Bladder Induced by Ovarian Hormone Deficiency from Rat Animal Model to Human Clinical Trial. **2021**, 22, 1
- 122 Increased Nectin-4 levels in chronic ketamine abusers and the relationship with lower urinary tract symptoms. **2021**, 87, 103714 2
- 121 Diagnosis of Overactive Bladder. **2021**, 13-25

120	Baseline Brain Segmental Volumes in Responders and Nonresponders to Anticholinergic Therapy for Overactive Bladder Syndrome. 2021 , 27, e399-e407	1
119	Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. 2016 , 11, e0147137	20
118	Effects of a Gentle, Self-Administered Stimulation of Perineal Skin for Nocturia in Elderly Women: A Randomized, Placebo-Controlled, Double-Blind Crossover Trial. 2016 , 11, e0151726	8
117	Analysis of the prevalence and associated factors of overactive bladder in adult Korean men. 2017 , 12, e0175641	12
116	Analysis of the prevalence of and factors associated with overactive bladder in adult Korean women. 2017 , 12, e0185592	11
115	A Study on Korean Medical Clinical Management of Female Overactive Bladder. 2014 , 27, 83-102	4
114	Can the lower urinary tract storage symptoms be completely resolved after plasmakinetic enucleation of the prostate?. 2017 , 19, 655-658	1
113	Clinical Evaluation of Urinary Incontinence. 2018 , 9, 55-64	2
112	Investigation of the reasons for withdrawal from long-term treatment with mirabegron of treatment-naïve Japanese female patients with overactive bladder in the real-world clinical setting. 2019 , 11, 149-154	1
111	Translation and Linguistic Validation of the Korean Version of the "Benefit, Satisfaction, and Willingness to Continue" Questionnaire for Patients With Overactive Bladder. 2016 , 20, 255-259	6
110	Potential Biomarkers for Diagnosis of Overactive Bladder Patients: Urinary Nerve Growth Factor, Prostaglandin E2, and Adenosine Triphosphate. 2017 , 21, 171-177	7
109	Korean version of the overactive bladder symptom score questionnaire: translation and linguistic validation. 2011 , 15, 135-42	45
108	The impact of overactive bladder on health-related quality of life, sexual life and psychological health in Korea. 2011 , 15, 143-51	37
107	Psychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population. 2012 , 16, 77-85	12
106	Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors. 2015 , 19, 171-7	11
105	Effects of Overactive Bladder Symptoms in Stroke Patients' Health Related Quality of Life and Their Performance Scale. 2017 , 41, 935-943	3
104	The Changes of Psychometric Profiles after Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. 2015 , 13, 269-74	1
103	Examination of Factors Affecting Decrease in the Frequency of Going Out in Community-dwelling Elderly. 2021 , 36, 725-731	

102 Urinary Incontinence. **2021**, 80, 187-193

101 Impact of urethroplasty on overactive bladder symptoms in patients with anterior urethral strictures. **2021**,

100 The safety and effectiveness of mirabegron in Parkinson's disease patients with overactive bladder: a randomized controlled trial. **2021**, 1-7

99 The surgical effect on overactive bladder symptoms in women with pelvic organ prolapse. **2021**, 11, 20193

98 Impact of Self-Perceived Bothersomeness, Quality of Life and Overactive Bladder. **2010**, 2195-2210

97 Sensory urgency. **2010**, 16, 313-9

96 Perspectives from Around the World: Panorama of Where We Are and Where We Are Going. **2011**, 177-193

95 [Screening test for overactive bladder in a newly developed comprehensive geriatric assessment initiative]. **2013**, 50, 249-57

94 A Study on Factors Influencing Medical Treatment Decision-Making for Overactive Bladders in Female Patients over 40 - Data from Clinical Trial Participants -. **2013**, 26, 69-81

93 Urinary Incontinence (UI). **2017**,

92 Translation and Linguistic Validation of the Korean Version of the Treatment Satisfaction Visual Analogue Scale and the Overactive Bladder Satisfaction With Treatment Questionnaire. **2017**, 21, 309-319

91 Combination Pharmacotherapy for Overactive Bladder. **2019**, 133-148

90 Sex Difference in Associations between Severity Level of Overactive Bladder and Perceived Stress, Depression in Korean Patients. **2019**, 44, 14-21

89 Clinical Trials for Sleep Disorders and Daytime Somnolence in Parkinson's Disease. **2021**, 271-291

88 The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan. **2021**, 1

87 Overview of the Evaluation of Lower Urinary Tract Dysfunction (LUTD). **2020**, 321-340

86 Comprehensive Review of Effective Application of Questionnaires for Clinical Research on Lower Urinary Tract Symptoms With Translation and Cultural Adaptation to the Korean Language. **2020**, 24, 313-323

85 The impact of adding solifenacin to tamsulosin therapy for treatment of storage lower urinary tract symptoms owing to benign prostatic hyperplasia. **2020**, 26,

84	Variable frequency stimulation of sacral neuromodulation in black-zone overactive bladder patients: a case report. 2020 , 9, 2842-2847	1
83	Urinary Incontinence and Voiding Dysfunction: Patient-Reported Outcome Assessment. 2021 , 249-262	
82	Improvement of health-related quality of life in patients with overactive bladder syndrome: A subanalysis of the prospective, noninterventional study BELIEVE in the Greek population. 2020 , 32, 135	
81	Effects of Additional Glycine in Outpatients Being Treated for Urine Storage Disorders. 2021 , 11, 381-392	
80	Mirabegron for the Treatment of Ureteral Stent-related Symptoms: A Systematic Review and Meta-analysis. 2021 ,	0
79	How international is the International Prostate Symptom Score? A literature review of validated translations of the IPSS, the most widely used self-administered patient questionnaire for male lower urinary tract symptoms. 2021 ,	0
78	Female urine incontinence: (VEL) effectiveness and safety. 2020 , 41,	0
77	The Effect of Korean Medical Treatment on the Overactive Bladder Syndrome with Coughing: Case Report. 2020 , 41, 724-733	
76	Reliability and validity of outcome measures used for urinary incontinence in patients with stroke: a narrative review. 2020 , 25, 305-315	
75	Efficacy and safety of Baweidihuang-wan in women with overactive bladder: a randomized, double blind, placebo controlled trial. 2014 , 7, 2744-53	2
74	Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms. 2015 , 8, 11863-70	2
73	Prevalence and predictors of nocturnal polyuria in females with overactive bladder syndrome. 2021 , 1	0
72	Assess the safety and effectiveness of a novel approach during transurethral pneumatic cystolithotripsy in large urinary bladder stone: quasi-clinical trial. 2021 , 1	
71	International Continence Society (ICS) report on the terminology for sexual health in men with lower urinary tract (LUT) and pelvic floor (PF) dysfunction.. 2022 , 41, 140-165	1
70	Japanese linguistic validation of the ureteral stent symptom questionnaire.. 2022 ,	
69	Construction of Progress Prediction Model of Urinary Incontinence in Elderly Women: Protocol for a Multi-Center, Prospective Cohort Study.. 2022 , 19,	0
68	Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P).. 2022 , 14,	1
67	The Er:YAG vaginal laser for management of women with genitourinary syndrome of menopause (GSM).. 2022 , 1	0

- 66 Lower Urinary Tract Symptoms are common after Artificial Urinary Sphincter implantation.. *Urology*, **2022**, 1.6 0
- 65 A non-interventional cross-sectional re-contact study investigating the relationship between overactive bladder and frailty in older adults in Japan.. **2022**, 22, 68
- 64 Clinical Correlation Between Overactive Bladder and Allergy in Children.. **2021**, 9, 813161
- 63 Frequency of overactive bladder (OAB) and the factors affecting it in patients with obstructive sleep apnea syndrome (OSAS).. **2022**, 3915603221078263
- 62 Hengli Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial.. **2022**, 13, 840695
- 61 Continuing posterior tibial nerve stimulation after twelve weekly sessions: a randomized controlled trial. **2022**, 34,
- 60 Effects of TORS-OSA Surgery on Lower Urinary Tract Symptoms, Overactive Bladder Symptoms, and Nocturia in Male Patients with Obstructive Sleep Apnea/Hypopnea Syndrome.. **2022**, 14, 547-556 0
- 59 Interplay between bladder microbiota and overactive bladder symptom severity: a cross-sectional study.. **2022**, 22, 39 0
- 58 Relationship between Urinary Calcium Excretion and Lower Urinary Tract Symptoms.. **2022**, 12, 0
- 57 Dutasteride add-on treatment to tadalafil for patients with benign prostatic enlargement is similarly effective as dutasteride add-on treatment to alpha blocker: a propensity-score matching analysis.. **2022**, 1 0
- 56 Development and validation of prediction model for incident overactive bladder: The Nagahama study.. **2022**,
- 55 Prevalence and factors associated with overactive bladder and stress urinary incontinence in the Japan Nurses' Health Study.. **2021**, 29, 1
- 54 Short-term efficacy and safety of second generation bipolar transurethral vaporization of the prostate (B-TUVP) for large benign prostate enlargement: Results from a retrospective feasibility study.. **2021**, 16, e0261586 2
- 53 Effect of the App-Based Video Guidance on Prenatal Pelvic Floor Muscle Training Combined with Global Postural Re-education for Stress Urinary Incontinence Prevention: A Protocol for a Multicenter, Randomized Controlled Trial.. **2021**, 18, 0
- 52 Insights into the development of a new index, vesical adaptation response to diuresis, for understanding lower urinary tract dysfunction.. **2021**, 0
- 51 Clinical Report of Baliao Electroacupuncture Treatment on a Stroke Patient Suffering from a Neurogenic Overactive Bladder. **2022**, 43, 90-103
- 50 Overactivity index: A noninvasive and objective outcome measure in overactive bladder in children.. **2022**,
- 49 Impact of combined usage of questionnaire forms with bladder diary for overactive bladder syndrome.. **2022**, 3915603221093913

- 48 Noninvasive spinal neuromodulation mitigates symptoms of idiopathic overactive bladder.. **2022**, 8, 5
- 47 Relevant predisposing factors for voiding in a sitting position among Japanese male adult patients. **2022**, 100030
- 46 The three-year evolution of overactive bladder syndrome in community-dwelling female residents aged 40 years and above. **2022**, 61, 479-484 ○
- 45 Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States.. **2022**, 50, 3000605221098176 ○
- 44 Retrospective analysis of second-generation bipolar transurethral vaporization of the prostate in older patients aged 80 years with benign prostate enlargement. **2022**, 100034 ○
- 43 Part II : Interactive case: Combination therapies in benign prostatic hyperplasia. **2022**, 5, 649-653
- 42 Evaluation of the efficacy of Lactobacillus-containing feminine hygiene products on vaginal microbiome and genitourinary symptoms in pre- and postmenopausal women: A pilot randomized controlled trial. 1
- 41 Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder. **2022**, 58, 825
- 40 Impact on quality of life in multiple sclerosis patients: Which urinary symptoms are to blame?. **2022**, ○
- 39 Are anterior mesh arms necessary in Japanese-style transvaginal mesh surgery for cystocele?. ○
- 38 Associations among Physician-Patient Communication, Patient Satisfaction, and Clinical Effectiveness of Overactive Bladder Medication: A Survey of Patients with Overactive Bladder. **2022**, 11, 4087
- 37 Relationship between the cross-sectional area of the lumbar dural sac and lower urinary tract symptoms: A population-based cross-sectional study. **2022**, 17, e0271479
- 36 The Clinical Effects of Pixel CO2 Laser on Bladder Neck and Stress Urinary Incontinence. **2022**, 11, 4971
- 35 Effectiveness of repetitive transcranial magnetic stimulation against poststroke urinary incontinence: a study protocol for a randomized controlled trial. **2022**, 23,
- 34 A new nomogram of urinary flow rate and volume based on multiple measurements per healthy adult Japanese men using a portable uroflowmeter (P-Flowdiary). **2022**, 22,
- 33 Long-term outcome of a pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack: study protocol. **2022**, 22,
- 32 Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial. **2022**, 12, ○
- 31 Latent Profile Analysis for Classification of Psychosomatic Symptoms in Perimenopausal Women. **2022**, ○

30	Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: A systematic review and meta-analysis. 14,	1
29	Use of low-intensity extracorporeal shock wave therapy in the management of interstitial cystitis/bladder pain syndrome patients: A thirty case study in a tertiary medical center.	0
28	LIMITATIONS OF QUESTIONNAIRE-BASED EVALUATION OF LOWER URINARY TRACT DYSFUNCTION IN ELDERLY PATIENTS. 2021 , 112, 185-191	0
27	Unraveling the impact of <i>Lactobacillus</i> spp. and other urinary microorganisms on the efficacy of mirabegron in female patients with overactive bladder. 12,	0
26	Feasibility and clinical implications of 3-day bladder diary derived classification of female storage lower urinary tract symptoms. 2022 , 12,	0
25	Association of right precuneus compression with apathy in idiopathic normal pressure hydrocephalus: a pilot study. 2022 , 12,	0
24	Age-specific effect of transurethral holmium laser enucleation of the prostate on overactive bladder in men with benign prostatic hyperplasia: An investigation using an overactive bladder symptom score.	0
23	Validation of acoustic voided volume measure: a pilot prospective study.	0
22	Efficacy of l -Arginine treatment in patients with HTLV-1-associated neurological disease.	0
21	Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot-assisted radical prostatectomy.	0
20	Parkinson's disease and nocturnal polyuria.	0
19	Evaluation of the efficacy of <i>Lactobacillus</i> -containing feminine hygiene products on vaginal microbiome and genitourinary symptoms in pre- and postmenopausal women: A pilot randomized controlled trial. 2022 , 17, e0270242	0
18	Physical activity and risk factors in subjects with overactive bladder. 2022 , 22, 32-39	0
17	Urinary dysfunction in patients with vascular cognitive impairment. 14,	0
16	Expanding the Bacterial Diversity of the Female Urinary Microbiome: Description of Eight New <i>Corynebacterium</i> Species. 2023 , 11, 388	0
15	Does acupuncture improve overactive bladder symptoms? A protocol for a qualitative study to explore patient experiences of receiving acupuncture for OAB symptoms. 2023 , 5, 100023	0
14	Evolution of erectile dysfunction in individuals infected with human T-lymphotropic virus 1: a prospective cohort study. 2023 , 20, 269-276	0
13	Comparison of traditional outcome measures and self-assessed goal achievement in patients treated surgically for benign prostatic hyperplasia.	0

- 12 Neurologic Manifestations of Common Variable Immunodeficiency. **2023**, 10, e200088 ○
- 11 Efficacy of Erbium YAG laser treatment in overactive bladder syndrome: a randomized controlled trial. **2023**, 30, 414-420 ○
- 10 The Relationship between the Presence of an Earlobe Crease and Overactive Bladder: A Cross-Sectional Case-Controlled Study. **2023**, 59, 476 ○
- 9 Enhancing urinary tract infection diagnosis for negative culture patients with metagenomic next-generation sequencing (mNGS). 13, ○
- 8 The peripheral nerve evaluation: determining which symptoms lead to a successful test. **2023**, 14, 26-29 ○
- 7 Postoperative functional and cancer control evaluation of conventional and Retzius-sparing robot-assisted radical prostatectomy: Comparison of selected cases by propensity score matching. **2023**, 83, 773-780 ○
- 6 Assessment of multidimensional healthcare parameters in Japanese adults for developing a virtual human generative model: protocol for an observational study (Preprint). ○
- 5 Comparison of micro-radiofrequency therapy and tolterodine for the treatment of newly diagnosed overactive bladder: A retrospective cohort study. 17, ○
- 4 Pattern of prefrontal cortical activation and network revealed by task-based and resting-state fNIRS in Parkinson's disease patients with overactive bladder symptoms. 17, ○
- 3 Efficacy and Tolerability of Ich Nieu Khang Dietary Supplement for Overactive Bladder. **2023**, 26, 262-269 ○
- 2 Assessment of Multidimensional Healthcare Parameters Among Adult Men and Women in Japan for Developing a Virtual Human Generative Model: Protocol for a Cross-Sectional Study (Preprint). ○
- 1 Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms: A randomized controlled trial. ○